Gencurix젠큐릭스

Gencurix is loss-making with a recent run of exchange filings on business suspension and a pending listing-eligibility review.

Gencurix sells liquid biopsy cancer diagnostic tests in Korea and overseas. Trailing twelve-month revenue is about ₩8.9B against an operating loss of about ₩5.4B, and the company had a free cash flow deficit of about ₩3.7B with only about ₩0.1B in cash. Its recent filings are dominated by business suspension reports and a listing-eligibility review.

What stands out

• Trailing revenue is about ₩8.9B, while operating income is about -₩5.4B, an operating margin of -60.4%.
• Full-year 2025 revenue rose 47% to about ₩7.5B, but the net loss was about -₩7.4B.
• The filings include Major Matters Reports on business suspension, amended in September and October 2026.
• A September 2026 filing covers a merger decision that was later amended, and the data does not explain the terms.
• The stock closed at ₩1,957, up 27% over three months and 23.4% over one year, but the 52-week high was ₩7,320 and the 52-week low is listed as ₩0, which is not a usable figure.
• Foreign ownership is 2% and the 20-day investor flows show retail net selling of about ₩67.8M.

What to watch

• The outcome of the substantive review of listing eligibility and the deadline for that decision, as flagged in the September and October 2026 notices.
• Details and status of the business suspension, and whether the merger and convertible bond actions proceed; the data does not state these terms.
• Next periodic results, since the data shows no forward estimates and no news headlines for the period.